OVERVIEW

In Case you Missed…Bridging Research to Practice in Retinal Disease Management is organized by Healio, Vindico Medical Education.

This enduring material is approved for 1 year from the date of original release, September 30, 2025, to September 29, 2026.

Description:
Patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) face ongoing challenges because of the chronic nature of these conditions and the intensive treatment burden associated with traditional anti-vascular endothelial growth factor (VEGF) therapies. While advanced treatments now offer extended dosing intervals and enhanced efficacy, adoption remains inconsistent, partly due to limited clinician awareness and disparities in access to care. Recently presented data at major scientific congresses, including Clinical Trials at the Summit and the American Society of Retina Specialists, have provided new insights into the safety, efficacy, and durability of therapies that can reduce treatment burden and improve real-world outcomes. As the evidence base continues to grow, ongoing education is essential to support the integration of new therapeutic approaches into clinical practice. In this CE activity, expert faculty evaluate recent data on extended dosing intervals and new therapeutic strategies to improve treatment selection and the management of patients with nAMD, DME, and DR.

Learning Objectives:
Upon successful completion of this activity, participants should be better able to:

Evaluate recent data on extended dosing intervals to improve the management of patients with nAMD.
Assess the latest findings to inform treatment selection for patients with DR.
Evaluate therapeutic strategies based on recent clinical evidence for managing patients with DME.